Last reviewed · How we verify

S-Ketamine 0.75

Turku University Hospital · FDA-approved active Small molecule

S-Ketamine 0.75 is a NMDA receptor antagonist Small molecule drug developed by Turku University Hospital. It is currently FDA-approved for Induction and maintenance of general anesthesia, Acute pain management. Also known as: Ketanest-S.

S-Ketamine is the active S-enantiomer of ketamine that acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor to produce rapid-onset anesthetic and analgesic effects.

S-Ketamine is the active S-enantiomer of ketamine that acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor to produce rapid-onset anesthetic and analgesic effects. Used for Induction and maintenance of general anesthesia, Acute pain management.

At a glance

Generic nameS-Ketamine 0.75
Also known asKetanest-S
SponsorTurku University Hospital
Drug classNMDA receptor antagonist
TargetNMDA receptor
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

S-Ketamine blocks NMDA receptors on glutamatergic neurons, which interrupts excitatory neurotransmission and produces dissociative anesthesia. The S-enantiomer is approximately 3-4 times more potent than the R-enantiomer at the NMDA receptor and is associated with faster onset and offset of action, making it suitable for clinical anesthesia and acute pain management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about S-Ketamine 0.75

What is S-Ketamine 0.75?

S-Ketamine 0.75 is a NMDA receptor antagonist drug developed by Turku University Hospital, indicated for Induction and maintenance of general anesthesia, Acute pain management.

How does S-Ketamine 0.75 work?

S-Ketamine is the active S-enantiomer of ketamine that acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor to produce rapid-onset anesthetic and analgesic effects.

What is S-Ketamine 0.75 used for?

S-Ketamine 0.75 is indicated for Induction and maintenance of general anesthesia, Acute pain management.

Who makes S-Ketamine 0.75?

S-Ketamine 0.75 is developed and marketed by Turku University Hospital (see full Turku University Hospital pipeline at /company/turku-university-hospital).

Is S-Ketamine 0.75 also known as anything else?

S-Ketamine 0.75 is also known as Ketanest-S.

What drug class is S-Ketamine 0.75 in?

S-Ketamine 0.75 belongs to the NMDA receptor antagonist class. See all NMDA receptor antagonist drugs at /class/nmda-receptor-antagonist.

What development phase is S-Ketamine 0.75 in?

S-Ketamine 0.75 is FDA-approved (marketed).

What are the side effects of S-Ketamine 0.75?

Common side effects of S-Ketamine 0.75 include Dissociation/emergence reactions, Increased heart rate, Increased blood pressure, Dizziness, Nausea.

What does S-Ketamine 0.75 target?

S-Ketamine 0.75 targets NMDA receptor and is a NMDA receptor antagonist.

Related